One has to have hug kahuna's to want to short a biotech in pivotal SOC end of phase 3 trial, thats at $1.70, The shorters could get creamed if we get a really postive NR or a major deal of any sort that DM has mentioned in the past, he has come through with deals in the past..... unless the shorter have inside info which i highly doubt , not sure 3rd eye would have invested 40 $ million Cad if they would certain of decent results in the trial....